Diagnosis and Treatment of Genitourinary Malignancies: Cancer Treatment and Research, cartea 88
Editat de Kenneth J. Pientaen Limba Engleză Paperback – 5 iun 2013
This volume attempts to summarize those advances which most impact us as clinicians, and has been divided into three sections. Section One, `Diagnostic advances: the use of molecular medicine in the diagnosis and prognosis of GU malignancies', details how epidemiologic studies and new molecular techniques are impacting our ability to diagnose and treat GU tumors. Section Two, `Surgical and radiation advances', details the recent major advances in the treatment of organ-confined cancers. Section Three, `Medical advances', addresses major issues in the treatment of metastatic disease. This volume will serve as a compendium of the advances, both at the basic science and clinical levels, which are currently impacting practicing oncologists and urologists.
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (1) | 1408.97 lei 6-8 săpt. | |
Springer Us – 5 iun 2013 | 1408.97 lei 6-8 săpt. | |
Hardback (1) | 1416.09 lei 6-8 săpt. | |
Springer Us – 31 dec 1996 | 1416.09 lei 6-8 săpt. |
Din seria Cancer Treatment and Research
- 5% Preț: 1103.03 lei
- 5% Preț: 726.32 lei
- 5% Preț: 787.58 lei
- 5% Preț: 1037.93 lei
- 5% Preț: 1032.64 lei
- 5% Preț: 1041.77 lei
- 5% Preț: 917.42 lei
- 5% Preț: 719.02 lei
- 5% Preț: 920.18 lei
- 5% Preț: 1040.88 lei
- 5% Preț: 721.19 lei
- 15% Preț: 700.10 lei
- 5% Preț: 370.38 lei
- 5% Preț: 2116.84 lei
- 5% Preț: 1414.08 lei
- 5% Preț: 1424.16 lei
- 5% Preț: 1106.69 lei
- 5% Preț: 1297.62 lei
- 5% Preț: 1103.22 lei
- 5% Preț: 1094.44 lei
- 5% Preț: 1096.45 lei
- 5% Preț: 1413.56 lei
- 5% Preț: 720.10 lei
- 5% Preț: 706.77 lei
- 5% Preț: 731.07 lei
- 5% Preț: 1414.80 lei
- 5% Preț: 1108.72 lei
- 5% Preț: 1098.12 lei
- 5% Preț: 1092.22 lei
- 5% Preț: 1099.56 lei
- 5% Preț: 1106.33 lei
- 5% Preț: 1096.81 lei
Preț: 1408.97 lei
Preț vechi: 1483.13 lei
-5% Nou
Puncte Express: 2113
Preț estimativ în valută:
269.64€ • 281.15$ • 224.09£
269.64€ • 281.15$ • 224.09£
Carte tipărită la comandă
Livrare economică 21 martie-04 aprilie
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9781461379133
ISBN-10: 146137913X
Pagini: 284
Ilustrații: VIII, 272 p.
Dimensiuni: 155 x 235 x 15 mm
Greutate: 0.4 kg
Ediția:1996
Editura: Springer Us
Colecția Springer
Seria Cancer Treatment and Research
Locul publicării:New York, NY, United States
ISBN-10: 146137913X
Pagini: 284
Ilustrații: VIII, 272 p.
Dimensiuni: 155 x 235 x 15 mm
Greutate: 0.4 kg
Ediția:1996
Editura: Springer Us
Colecția Springer
Seria Cancer Treatment and Research
Locul publicării:New York, NY, United States
Public țintă
ResearchCuprins
DIAGNOSTIC Advances: The Use of Molecular Medicine in the Diagnosis and Prognosis of Genitourinary Malignancies.- 1. Epidemiology of prostate cancer and bladder cancer: An Overview.- 2. Von Hippel-Lindau syndrome: hereditary cancer arising from Inherited mutations of the VHL tumor suppressor gene.- 3. New pathologic techniques for diagnosing genitourinary Malignancies.- 4. Reverse transcriptase-polymerase chain reaction (RT-PCR) to detect prostate cancer micrometastasis in the blood.- 5. Successful separation between benign prostatic hyperplasia and prostate cancer by measurement of free and complexed PSA.- Surgical and Radiation Advances.- 6. Retroperitoneal lymphadenectomy in staging and treatment of clinical stage I and II nonseminomatous testis cancer (NSGCT): the development of nerve-sparing techniques.- 7. Current therapy for invasive bladder cancer.- 8. Beyond the nerve-sparing radical prostatectomy.- 9. Three-dimensional conformal therapy (3D-CRT) for prostate cancer.- 10. Cryosurgical ablation of the prostate: treatment alternative for localized prostate cancer.- Medical Advances.- 11. The chemoprevention of prostate cancer and the prostate cancer prevention trial.- 12. Total androgen blockade for prostate cancer: the end does not justify the means.- 13. Therapy for hormone-resistant prostate cancer no longer a myth.- 14. Renal, bladder, and prostate cancers: gene therapy.- 15. The role of immunotherapy in urologic malignancies.- 16. Assessing health-related quality of life in patients with genitourinary malignancies.